Inhibitors of mTOR overcome drug resistance from topoisomerase II inhibitors in solid tumors
- PMID: 21764510
- DOI: 10.1016/j.canlet.2011.06.005
Inhibitors of mTOR overcome drug resistance from topoisomerase II inhibitors in solid tumors
Abstract
The present study was performed to investigate the possible role of mTOR inhibitors in restoring chemosensitivity to adriamycin/cisplatin and elucidate the underlying mechanism. Combining adriamycin/cisplatin with torisel synergistically inhibited the cell proliferation in human oropharyngeal carcinoma cell line KB and its multidrug-resistant subclone KB/7D. Combining adriamycin and torisel inhibited the phosphorylation of 4EBP-1 and p70S6K, the proteins involved in mTOR pathway, increased expression of γH2AX indicative of DNA damage, triggered cell cycle arrest at G2/M and apoptosis. We conclude that chromatin decondensation by DNA damage provided an easy access for torisel to block the translation of proteins essential for DNA repair thereby restoring the chemosensitivity.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.
Similar articles
-
Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.Cancer Res. 2005 Nov 1;65(21):9953-61. doi: 10.1158/0008-5472.CAN-05-0921. Cancer Res. 2005. PMID: 16267020
-
The mTOR inhibitor RAD001 sensitizes tumor cells to the cytotoxic effect of carboplatin in breast cancer in vitro.Anticancer Res. 2011 Sep;31(9):2713-22. Anticancer Res. 2011. PMID: 21868512
-
mTOR inhibitors show promising in vitro activity in bladder cancer and head and neck squamous cell carcinoma.Oncol Rep. 2011 Mar;25(3):763-8. doi: 10.3892/or.2011.1146. Epub 2011 Jan 14. Oncol Rep. 2011. PMID: 21240463
-
Overcoming endocrine resistance in breast cancer: importance of mTOR inhibition.Expert Rev Anticancer Ther. 2012 Dec;12(12):1579-89. doi: 10.1586/era.12.138. Expert Rev Anticancer Ther. 2012. PMID: 23253223 Review.
-
Targeting endocrine resistance: is there a role for mTOR inhibition?Clin Breast Cancer. 2010 Nov;10 Suppl 3:S79-85. doi: 10.3816/CBC.2010.s.016. Clin Breast Cancer. 2010. PMID: 21115426 Review.
Cited by
-
Mechanisms of drug resistance in acute myeloid leukemia.Onco Targets Ther. 2019 Mar 11;12:1937-1945. doi: 10.2147/OTT.S191621. eCollection 2019. Onco Targets Ther. 2019. PMID: 30881045 Free PMC article. Review.
-
A phase I study of pegylated liposomal doxorubicin and temsirolimus in patients with refractory solid malignancies.Cancer Chemother Pharmacol. 2014 Aug;74(2):419-26. doi: 10.1007/s00280-014-2493-x. Epub 2014 Jun 11. Cancer Chemother Pharmacol. 2014. PMID: 24916546 Free PMC article. Clinical Trial.
-
MiR-497 decreases cisplatin resistance in ovarian cancer cells by targeting mTOR/P70S6K1.Oncotarget. 2015 Sep 22;6(28):26457-71. doi: 10.18632/oncotarget.4762. Oncotarget. 2015. PMID: 26238185 Free PMC article.
-
mTOR inhibitors: A novel class of anti-cancer agents.Infect Agent Cancer. 2012 Jan 3;7(1):1. doi: 10.1186/1750-9378-7-1. Infect Agent Cancer. 2012. PMID: 22214493 Free PMC article. No abstract available.
-
Reciprocal regulation of autophagy and dNTP pools in human cancer cells.Autophagy. 2014 Jul;10(7):1272-84. doi: 10.4161/auto.28954. Epub 2014 May 16. Autophagy. 2014. PMID: 24905824 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous